Result of General Meeting
Oxford BioDynamics Plc announced that resolutions for a placing were passed at a General Meeting, leading to the application for admission of 9,150,000,000 new Ordinary Shares to AIM, expected on 27 August 2026. Following admission, the Company's total issued ordinary share capital will be 13,440,910,967 shares. Directors and Persons Discharging Managerial Responsibilities (PDMRs) participated in the placing, with Martin Diggle acquiring 500,000,000 shares, Richard Compton 300,000,000, Iain Ross 100,000,000, Dr. Alexandre Akoulitchev 30,000,000, and Paul Stockdale 25,000,000, all at a price of £0.001 per share.
Select text to share a quote on X · sign in to keep highlights & notes in your OBD notes
Oxford, UK - 26 August 2026 - Oxford BioDynamics Plc (AIM: OBD), the international biotechnology company advancing personalised healthcare through precision clinical diagnostic tests and EpiSwitch® Orion, its cloud-based 3D genomics platform for pharma and biotech partners, announces that the resolutions proposed at the General Meeting of the Company, held earlier today, pursuant to the Placing announced on 10 August 2026, were duly passed.
Accordingly, an application has been made to the London Stock Exchange for 9,150,000,000 new Ordinary Shares of £0.001 each in the capital of the Company, to be admitted to trading on AIM.
It is expected that Admission will take place, and trading in the Placing Shares will commence, at 8.00 a.m. on 27 August 2026. Following Admission, the Company's issued ordinary share capital and total voting rights will consist of 13,440,910,967 Ordinary Shares. This figure should be used by shareholders as the denominator for the calculation by which they determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
The total new Ordinary Shares subscribed for pursuant to the Placing by the Directors and PDMRs who are participating in the Placing, are set out below:
| Director/PDMR | Existing beneficial shareholding | Placing Shares | Beneficial shareholding following the Placing | Shareholding as a percentage of the Enlarged Ordinary Share Capital |
|---|---|---|---|---|
| Martin Diggle 1 | 618,542,844 | 500,000,000 | 1,118,542,844 | 8.32% |
| Richard Compton | 0 | 300,000,000 | 300,000,000 | 2.2% |
| Iain Ross | 23,333,333 | 100,000,000 | 123,333,333 | 0.9% |
| Dr. Alexandre Akoulitchev | 14,228,962 | 30,000,000 | 44,228,962 | 0.3% |
| Paul Stockdale | 6,411,252 | 25,000,000 | 31,411,252 | 0.2% |
1 Martin Diggle's beneficial holding is held through the Vulpes Life Sciences Fund and Vulpes Testudo Fund, which are controlled by him.
Capitalised terms used but not otherwise defined in this announcement have the meanings set out in the Circular published on 10 August 2026.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | 1) Iain Ross 2) Richard Compton 3) Dr. Alexandre Akoulitchev 4) Paul Stockdale 5) Martin Diggle |
| 2 | Reason for the notification | |
| a) | Position/status | 1) Non-Executive Chairman 2) Chief Executive Officer 3) Chief Scientific Officer 4) Chief Financial Officer 5) Non-Executive Director |
| b) | Initial notification / Amendment | Initial Notification |
| a) | Name | Oxford BioDynamics Plc |
| b) | LEI | 2138005Y1TK258O5U928 |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.001 each ISIN: GB00BD5H8572 |
| b) | Nature of the transaction | Purchase of ordinary shares |
| c) | Price(s) and volume(s) | Prices Volumes 1. £0.001 100,000,000 2. £0.001 300,000,000 3. £0.001 30,000,000 4. £0.001 25,000,000 5. £0.001 500,000,000 |
| d) | Aggregated information | N/A - each a single transaction |
| e) | Date of the transaction | 26 August 2026 |
| f) | Place of the transaction | London Stock Exchange, AIM (AIMX) |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.